WO2009014100A1 - ｐ２７蛋白質誘導剤 - Google Patents

ｐ２７蛋白質誘導剤 Download PDF

Info

Publication number
WO2009014100A1
WO2009014100A1 PCT/JP2008/063053 JP2008063053W WO2009014100A1 WO 2009014100 A1 WO2009014100 A1 WO 2009014100A1 JP 2008063053 W JP2008063053 W JP 2008063053W WO 2009014100 A1 WO2009014100 A1 WO 2009014100A1
Authority
WO
WIPO (PCT)
Prior art keywords
protein inducer
oxygen atom
inducer
protein
group
Prior art date
Application number
PCT/JP2008/063053
Other languages
English (en)
French (fr)
Inventor
Toshiyuki Sakai
Hitoshi Iikura
Ikumi Hyoudoh
Toshihiro Aoki
Noriyuki Furuichi
Masayuki Matsushita
Fumio Watanabe
Sawako Ozawa
Masahiro Sakaitani
Pil-Su Ho
Yasushi Tomii
Kenji Takanashi
Naoki Harada
Original Assignee
Chugai Seiyaku Kabushiki Kaisha
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Seiyaku Kabushiki Kaisha filed Critical Chugai Seiyaku Kabushiki Kaisha
Priority to JP2009524476A priority Critical patent/JP5325103B2/ja
Priority to EP08791362.0A priority patent/EP2172198B1/en
Priority to KR1020107000227A priority patent/KR101511396B1/ko
Priority to US12/669,944 priority patent/US8569378B2/en
Publication of WO2009014100A1 publication Critical patent/WO2009014100A1/ja

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

　本発明は、下記一般式（１１）で表される化合物又はその薬学上許容しうる塩を有効成分とするｐ２７蛋白質誘導剤を提供する。 〔式中、Ｇ１、Ｇ２、Ｇ３及びＧ８は、それぞれ独立に、－Ｎ＝等から選択され、環Ｇ６は２価のアリール基等から選択され、Ａはアミノ基等から選択され、Ｇ４は酸素原子等から選択され、Ｇ５は酸素原子等から選択され、Ｇ７は－ＣＨ２－等から選択され、Ｒ２はＣ１－６アルキル基等から選択される。〕
PCT/JP2008/063053 2007-07-20 2008-07-18 ｐ２７蛋白質誘導剤 WO2009014100A1 (ja)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2009524476A JP5325103B2 (ja) 2007-07-20 2008-07-18 ｐ２７蛋白質誘導剤
EP08791362.0A EP2172198B1 (en) 2007-07-20 2008-07-18 p27 PROTEIN INDUCER
KR1020107000227A KR101511396B1 (ko) 2007-07-20 2008-07-18 ｐ27 단백질 유도제
US12/669,944 US8569378B2 (en) 2007-07-20 2008-07-18 p27 protein inducer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007-189480 2007-07-20
JP2007189480 2007-07-20

Publications (1)

Publication Number Publication Date
WO2009014100A1 true WO2009014100A1 (ja) 2009-01-29

Family

ID=40281351

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/063053 WO2009014100A1 (ja) 2007-07-20 2008-07-18 ｐ２７蛋白質誘導剤

Country Status (5)

Country Link
US (1) US8569378B2 (ja)
EP (1) EP2172198B1 (ja)
JP (1) JP5325103B2 (ja)
KR (1) KR101511396B1 (ja)
WO (1) WO2009014100A1 (ja)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011111831A1 (ja) * 2010-03-12 2011-09-15 日本曹達株式会社 ピリジン環含有化合物、及びハロゲン化ピコリン誘導体及びテトラゾリルオキシム誘導体の製造方法
WO2012171488A1 (en) * 2011-06-17 2012-12-20 Beijing Hanmi Pharmaceutical Co., Ltd. Coumarin derivative, pharmaceutical composition and use thereof
WO2013035754A1 (ja) 2011-09-05 2013-03-14 中外製薬株式会社 クマリン誘導体の製造方法
WO2014046224A1 (ja) * 2012-09-21 2014-03-27 日本臓器製薬株式会社 クマリン誘導体
JP2015193610A (ja) * 2014-03-20 2015-11-05 日本臓器製薬株式会社 クマリン誘導体を含有する医薬
JP2016516702A (ja) * 2013-03-13 2016-06-09 ザ リージェンツ オブ ザ ユニバーシティー オブ ミシガン Ｍｅｋ／ｐｉ３ｋ二重阻害剤および該阻害剤を使用する治療方法
WO2017024167A1 (en) 2015-08-04 2017-02-09 Dow Agrosciences Llc Process for fluorinating compounds
WO2019096397A1 (en) 2017-11-16 2019-05-23 The Institute Of Cancer Research: Royal Cancer Hospital Coumarin derivative for therapy or prophylaxis of a cell proliferative disorder
EP3594199A1 (en) 2018-07-09 2020-01-15 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Crystalline 2-fluoro-3-nitrotoluene and process for the preparation thereof
WO2021047783A1 (en) 2019-09-13 2021-03-18 The Institute Of Cancer Research: Royal Cancer Hospital Vs-6063 in combination with ch5126766 for the treatment of cancer
CN114560774A (zh) * 2020-11-27 2022-05-31 瑞博(杭州)医药科技有限公司 一种2-氟-3-硝基苯甲酸的合成方法
WO2023133472A1 (en) * 2022-01-06 2023-07-13 Immuneering Corporation Mek immune oncology inhibitors and therapeutic uses thereof
US11873296B2 (en) 2022-06-07 2024-01-16 Verastem, Inc. Solid forms of a dual RAF/MEK inhibitor

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014151953A1 (en) 2013-03-15 2014-09-25 The California Institute For Biomedical Research Compounds and methods for inducing chondrogenesis
CN104059378B (zh) * 2014-06-27 2016-04-20 安徽大学 一种六位取代的香豆素衍生物双光子荧光染料及其制备方法
CN104119690B (zh) * 2014-06-27 2016-06-29 安徽大学 一种七位取代的香豆素衍生物双光子荧光染料及其制备方法
CN107200716B (zh) * 2016-03-17 2020-04-17 北京大学 苯并噁嗪类化合物及其制备方法与应用
US10919877B2 (en) 2016-07-06 2021-02-16 The Regents Of The University Of Michigan Multifunctional inhibitors of MEK/PI3K and mTOR/MEK/PI3K biological pathways and therapeutic methods using the same
US10865201B2 (en) 2016-09-12 2020-12-15 Valo Health, Inc. Bicyclic compounds useful as GPR120 modulators
WO2018049324A1 (en) 2016-09-12 2018-03-15 Numerate, Inc. Monocyclic compounds useful as gpr120 modulators
CN108003112B (zh) * 2017-12-23 2021-03-19 宁夏蓝博思化学技术有限公司 一种杂环脲类吲哚胺-2,3-双加氧酶抑制剂中间体制备方法
US10730885B1 (en) 2019-04-30 2020-08-04 King Saud University Coumarin derivatives
BR112022013593A2 (pt) * 2020-01-10 2022-09-13 Immuneering Corp Inibidores de mek e usos terapêuticos dos mesmos
CN113024384A (zh) * 2021-03-16 2021-06-25 湖南工程学院 一种2-氟-3-硝基苯甲酸中间体原料的合成方法
CN118574826A (zh) * 2022-01-26 2024-08-30 南京明德新药研发有限公司 香豆素类化合物及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002008217A2 (en) 2000-07-21 2002-01-31 Chugai Seiyaku Kabushiki Kaisha COUMARIN DERIVATIVES USEFUL AS TNFα INHIBITORS
WO2005121142A1 (en) * 2004-06-11 2005-12-22 Japan Tobacco Inc. 5-amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2h-pyrido’2,3-d! pyrimidine derivatives and related compounds for the treatment of cancer
WO2007091736A1 (ja) * 2006-02-09 2007-08-16 Chugai Seiyaku Kabushiki Kaisha 抗腫瘍活性を有する新規クマリン誘導体

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUT63843A (en) 1992-02-13 1993-10-28 Biosignal Kutato Fejlesztoe Kf Process for producing new kumarin derivatives and their analogs inhibiting mammal cell proliferation and tumour growth, as well as pharmaceutical comkpositions comprising such compounds
US5624951A (en) 1992-09-01 1997-04-29 Pfizer Inc. 4-hydroxy coumarin derivatives with antibacterial activity
DE4233963A1 (de) 1992-10-08 1994-04-14 Schwabe Willmar Gmbh & Co Neue Benzopyranone, Verfahren zu ihrer Herstellung und Verwendung
IL108459A0 (en) 1993-02-05 1994-04-12 Opjohn Company 4-Hydroxy-benzopyran-2-ones and 4-hydroxy-cycloalkyl [B] pyran-2-ones useful for treating infections due to hiv and other retroviruses
FR2763944B1 (fr) 1997-06-03 2000-12-15 Centre Nat Rech Scient Nouveaux derives de coumarines, leurs procedes de preparation et leur application comme medicaments en tant qu'inhibiteurs de proteases
GB9722600D0 (en) 1997-10-24 1997-12-24 Bio Monde Holdings Internation Pharmaceutical compositon
US6331562B1 (en) 1998-12-30 2001-12-18 Signal Pharmaceuticals, Inc. Compounds and methods for modulation of estrogen receptors
ATE388143T1 (de) 2001-04-24 2008-03-15 Aryx Therapeutics Cumarin derivate und ihre verwendung als anticoagulantien
US7411076B2 (en) 2001-09-12 2008-08-12 Institute Of Medicinal Molecular Design, Inc. Coumarin derivative
US7148252B2 (en) 2001-10-03 2006-12-12 Signal Pharmaceuticals, Llc Use of benzopyranones for treating or preventing a primary brain cancer or a brain metastasis
KR20040081123A (ko) 2002-01-11 2004-09-20 다케다 야쿠힌 고교 가부시키가이샤 쿠마린 유도체, 이의 제조 방법 및 용도
FR2849653B1 (fr) 2003-01-08 2006-08-25 B F B Etudes Et Rech S Experim Derives de la coumarine ayant une affinite pour les recepteurs aux estrogenes, procede pour leur preparation et compositions pharmaceutiques en contenant
JP2005162727A (ja) 2003-03-18 2005-06-23 Sankyo Co Ltd スルファミド誘導体及びその医薬組成物
US20050054586A1 (en) 2003-06-30 2005-03-10 Bartels Stephen P. Treatment of ophthalmic disorders
CN101142203A (zh) 2005-01-21 2008-03-12 詹森药业有限公司 用作离子通道开放剂的新香豆素衍生物
CA2618218C (en) 2005-07-21 2015-06-30 Ardea Biosciences, Inc. N-(arylamino)-sulfonamide inhibitors of mek
WO2007121269A2 (en) 2006-04-11 2007-10-25 Ardea Biosciences, Inc. N-aryl-n'alkyl sulfamides as mek inhibitors
JP2009079039A (ja) 2007-09-05 2009-04-16 Sumitomo Chemical Co Ltd クマリン化合物及びその用途
JP2009062300A (ja) 2007-09-05 2009-03-26 Sumitomo Chemical Co Ltd クマリン化合物及びその用途
US7893081B2 (en) 2007-12-20 2011-02-22 Merck & Co., Inc. Tyrosine kinase inhibitors

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002008217A2 (en) 2000-07-21 2002-01-31 Chugai Seiyaku Kabushiki Kaisha COUMARIN DERIVATIVES USEFUL AS TNFα INHIBITORS
JP2004509855A (ja) * 2000-07-21 2004-04-02 中外製薬株式会社 ＴＮＦαインヒビターとして有用なクマリン誘導体
WO2005121142A1 (en) * 2004-06-11 2005-12-22 Japan Tobacco Inc. 5-amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2h-pyrido’2,3-d! pyrimidine derivatives and related compounds for the treatment of cancer
WO2007091736A1 (ja) * 2006-02-09 2007-08-16 Chugai Seiyaku Kabushiki Kaisha 抗腫瘍活性を有する新規クマリン誘導体

Non-Patent Citations (57)

* Cited by examiner, † Cited by third party
Title
BABA, M.; JIN, Y; MIZUNO, A.; SUZUKI, H.; OKADA, Y; TAKASUKA, N.; TOKUDA, H.; NISHINO, H.; OKUYAMA, T., BIOL. PHARM. BULL., vol. 25, 2002, pages 244 - 246
BIOORGANIC AND MEDICINAL CHEMISTRY LETTERS, vol. 12, 2002, pages 2109 - 2112
BIOORGANIC AND MEDICINAL CHEMISTRY LETTERS, vol. 14, 2004, pages 2411 - 2415
BIOORGANIC AND MEDICINAL CHEMISTRY LETTERS, vol. 16, 2004, pages 1411 - 1416
BIOORGANIC AND MEDICINAL CHEMISTRY, vol. 13, 2005, pages 1393 - 1402
BUDZISZ, E.; MALECKA, M.; LORENZ, I-P.; MAYER, P.; KWIECIEN, R. A.; PANETH, P.; KRAJEWSKA, U.; ROZALSKI, M., INORGANIC CHEMISTRY, vol. 45, 2006, pages 9688 - 9695
CHATURVEDULA, V S. P.; SCHILLING, J. K.; KINGSTON, D. G. I., J. NAT. PROD., vol. 65, 2002, pages 965 - 972
CHEMICAL AND PHARMACEUTICAL BULLETIN, vol. 52, 2004, pages 818 - 829
CHEN, S.; CHO, M.; KARLSBERG, K.; ZHOU, D.; YUAN, Y C., J. BIOL. CHEM., vol. 279, 2004, pages 48071 - 48078
CHEN, Y-C.; CHENG, M-J.; LEE, S-J.; DIXIT, A-K.; ISHIKAWA, T.; TSAI, I-L.; CHEN, I-S., HELV. CHIM. ACTA, vol. 87, 2004, pages 2805 - 2811
CHEN, Y-L.; WANG, T-C.; TZENG, C-C., HELV. CHIM. ACTA, vol. 82, 1999, pages 191 - 197
CHENG, J. F.; CHEN, M.; WALLACE, D.; TITH, S.; ARRHENIUS, T.; KASHIWAGI, H.; ONO, Y; ISHIKAWA, A.; SATO, H.; KOZONO, T., BIOORG. MED. CHEM. LETT., vol. 14, 2004, pages 2411 - 2415
CORSINI, E.; LUCCHI, L.; BINAGLIA, M.; VIVIANI, B.; BEVILACQUA, C.; MONASTRA, G; MARINOVICH, M.; GALLI, C. L., EUR. J. PHARMACOL., vol. 418, 2001, pages 231 - 237
CUZZOCREA, S.; MAZZON, E.; BEVILAQUA, C.; COSTANITINO, G; BRITTI, D.; MAZZULLO, G; DE SARRO, A.; CAPUTI, A. P., BR. J. PHARMACOL., vol. 131, 2000, pages 1399 - 1407
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 34, 1999, pages 1003 - 1008
FINN, G J.; CREAVEN, B. S.; EGAN, D. A., CANCER LETTERS, vol. 214, 2004, pages 43 - 54
FINN, G J.; CREAVEN, B. S.; EGAN, D. A., EURO. J. PHARMACOL., vol. 481, 2003, pages 159 - 167
FRIES, W.; MAZZON, E.; STURIALE, S.; GIOFRE, M. R.; LO PRESTI, M. A.; CUZZOCREA, S.; CAMPO, G. M.; CAPUTI, A. P.; LONGO, G; STUMIO, LIFE SCI., vol. 74, 2004, pages 2749 - 2756
HAN, S.; ZHOU, V; PAN, S.; LIU, Y; HORNSBY, M.; MCMULLAN, D.; KLOCK, H. E.; HAUGEN, J.; LESLEY, S. A.; GRAY, N., BIOORG. MED. CHEM. LETT., vol. 15, 2005, pages 5467 - 5473
INOUE, T.; KAMIYAMA, J.; SAKAI, T., J. BIOL. CHEM., vol. 274, 1999, pages 32309 - 32317
ITO, C.; ITOIGAWA, M.; MISHINA, Y; FILHO, V. C.; ENJO, F.; TOKUDA, H.; NISHINO, H.; FURUKAWA, H., J. NAT. PROD., vol. 66, 2003, pages 368 - 371
JERRY MARCH: "Advanced Organic Chemistry", WILEY INTERSCIENCE
JOURNAL OF ANTIBIOTICS, vol. 47, 1994, pages 1456 - 1465
JOURNAL OF FLUORINE CHEMISTRY, vol. 120, 2003, pages 173 - 183
JOURNAL OF MEDICINAL CHEMISTRY, vol. 47, 2004, pages 6447 - 6450
JOURNAL OF ORGANIC CHEMISTRY, vol. 51, 1986, pages 3242 - 3244
JOURNAL OF ORGANIC CHEMISTRY, vol. 64, 1999, pages 6921 - 6923
KAJIYAMA, J.; INOUE, T.; OHTANI-FUJITA, N.; MINAMI, S.; YAMAGISHI, H.; SAKAI, T., FEBS LETTER, vol. 455, 1999, pages 281 - 285
KEMPEN, I.; PAPAPOSTOLOU, D.; THIERRY, N.; POCHET, L; COUNEROTTE, S.; MASEREEL, B.; FOIDART, J. M.; RAVAUX, M. R.; NOEUL, A.; PIRO, BR. J. CANCER, vol. 88, 2003, pages 1111 - 1118
KIM, H. H.; BANG, S. S.; GHOI, J. S.; HAN, H.; KIM, I-H., CANCER LETTERS, vol. 223, 2005, pages 191 - 201
KIMURA, S.; ITO, C.; JYOKO, N.; SEGAWA, H.; KURODA, J.; OKADA, M.; ADACHI, S.; NAKAHATA, T.; YUASA, T.; FILHO, V C., INT. J. CANCER, vol. 113, 2005, pages 158 - 165
KULKARNI, M. V; KULKARNI, G. M.; LIN, C-H.; SUN, C-M, CURRENT MEDICINAL CHEMISTRY, vol. 13, 2006, pages 2795 - 2818
LEE, K-H.; CHAI, H-B.; TAMEZ, P. A.; PEZZUTO, J. M.; CORDELL, G. A.; WIN, K. K.; TIN-WA, M., PHYTOCHEMISTRY, vol. 64, 2003, pages 535 - 541
LEE, S.; SIVAKUMAR, K.; SHIN, W-S.; XIE, F.; WANG, Q., BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 16, 2006, pages 4596 - 4599
LIEBIGS ANNALEN CHEMIE, vol. 4, 1979, pages 554 - 563
LLOYD, M. D.; PEDERICK, R. L.; NATESH, R.; WOO, L. W. L.; PUROHIT, A.; REED, M. J.; ACHARYA, K. R.; POTTER, B. V L., BIOCHEM. J., vol. 385, 2005, pages 715 - 720
LOPEZ-PEREZ, J. L.; OLMEDO, D. A.; OLMO, E. D.; VASQUEZ, Y; SOLIS, P. N.; GUPTA, M. P.; FELICIANO, A. S., J. NAT. PROD., vol. 68, 2005, pages 369 - 373
MADARI, H.; PANDA, D.; WILSON, L.; JACOBS, R. S., CANCER RESEARCH, vol. 63, 2003, pages 1214 - 1220
MAZZEI, M.; MIELE, M.; NIEDDU, E.; BARBIERI, F.; BRUZZO, C.; ALAMA, A., EUR. J. MED. CHEM., vol. 36, 2001, pages 915 - 923
MINAMI, S.; OHTANI-FUJITA, N.; IGATA, E.; TAMAKI, T.; SAKAI, T., FEBS LETTER, vol. 411, 1997, pages 1 - 6
NASU, K.; KOHSAKA, H.; NONOMURA, Y; TERADA, Y; ITO, H.; HIROKAWA, K., J. IMMUNOL., vol. 165, 2000, pages 7246 - 7252
NONOMURA, Y; KOHSAKA, H.; NASU, K.; TERADA, Y; IKEDA, M.; MIYASAKA, N., INT. IMMUNOL., vol. 13, 2001, pages 723 - 731
ORGANIC LETTERS, vol. 4, 2002, pages 4689 - 4692
ORGANIC PREPARATIONS AND PROCEDURES INTERNATIONAL, vol. 36, 2004, pages 347 - 351
PUROHIT, A.; WOO, L. W. L.; CHANDER, S. K.; NEWMAN, S. P.; IRESON, C.; HO, Y; GRASSO, A.; LEESE, M. P.; POTTER, B. V. L.; REED, M., J. STEROID BIOCHEM. MOL. BIOL., vol. 86, 2003, pages 423 - 432
PUROHIT, A.; WOO, L. W. L.; POTTER, B. V L.; REED, M. J., CANCER RESEARCH, vol. 60, 2000, pages 3394 - 3396
REDDY, N. S.; GUMIREDDY, K.; MALLIREDDIGARI, M. R.; COSENZA, S. C.; VENKATAPURAM, P.; BELL, S. C.; REDDY, E. P.; REDDY, M. V. R., BIOORG. MED. CHEM., vol. 13, 2005, pages 3141 - 3147
REDDY, N. S.; MALLIREDDIGARI, M. R.; COSENZA, S. C.; GUMIREDDY, K.; BELL, S. C.; REDDY, E. P.; REDDY, M. V. R., BIOORG. MED. CHEM. LETT., vol. 14, 2004, pages 4093 - 4097
RIVEIRO, M. E.; SHAYO, C.; MONCZOR, F.; FERNANDEZ, N.; BALDI, A.; DE KIMPE, N.; ROSSI, J.; DEBENEDETTI, S.; DAVIO, C., CANCER LETTERS, vol. 210, 2004, pages 179 - 188
SYNTHESIS, vol. 17, 2002, pages 2561 - 2578
T. W. GREENE; P. G. M. WUTS: "Protective Groups in Organic Synthesis", 1991, JOHN WILEY AND SONS, INC.
TADA, Y; SHIKISHIMA, Y; TAKAISHI, Y; SHIBATA, H.; HIGUTI, T.; HONDA, G; ITO, M.; TAKEDA, Y; KODZHIMATOV, O. K.; ASHURMETOV, O., PHYTOCHEMISTRY, vol. 59, 2002, pages 649 - 654
TANIGUCHI, K.; KOHSAKA, H.; INOUE, N.; TERADA, Y; ITO, H.; HIROKAWA, K., NAT. MED., vol. 5, 1999, pages 760 - 767
VIJAYA, K. P.; RAJESWAR, R. V.: "Indian Journal of Chemistry", SECTION B: ORGANIC CHEMISTRY INCLUDING MEDICINAL CHEMISTRY, vol. 44B, 2005, pages 2120 - 2125
WOO, L. W. L.; HOWARTH, N. M.; PUROHIT, A.; HEJAZ, A. M.; REED, M. J.; POTTER, B. V. L., J. MED. CHEM., vol. 41, 1998, pages 1068 - 1083
WOO, L. W. L.; PUROHIT, A.; REED, M. J.; POTTER, B. V. L., J. MED. CHEM., vol. 39, 1996, pages 1349 - 1351
YAKUGAKU ZASSHI, vol. 75, 1955, pages 292 - 296

Cited By (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014139183A (ja) * 2010-03-12 2014-07-31 Nippon Soda Co Ltd ハロゲン化ピコリン誘導体の製造方法
US9018385B2 (en) 2010-03-12 2015-04-28 Nippon Soda Co., Ltd. Compound containing pyridine ring and method for producing halogenated picoline derivative and tetrazolyloxime derivative
CN102791691B (zh) * 2010-03-12 2015-06-03 日本曹达株式会社 含有吡啶环的化合物、及卤代甲基吡啶衍生物以及四唑基肟衍生物的制造方法
CN104072408B (zh) * 2010-03-12 2016-09-14 日本曹达株式会社 含有吡啶环的化合物、及卤代甲基吡啶衍生物以及四唑基肟衍生物的制造方法
AU2011225122B2 (en) * 2010-03-12 2013-11-07 Nippon Soda Co., Ltd. Compound containing pyridine ring and method for producing halogenated picoline derivative and tetrazolyloxime derivative
AU2011225122B8 (en) * 2010-03-12 2013-12-12 Nippon Soda Co., Ltd. Compound containing pyridine ring and method for producing halogenated picoline derivative and tetrazolyloxime derivative
CN104130184B (zh) * 2010-03-12 2016-06-15 日本曹达株式会社 含有吡啶环的化合物、及卤代甲基吡啶衍生物以及四唑基肟衍生物的制造方法
KR101409137B1 (ko) * 2010-03-12 2014-06-17 닛뽕소다 가부시키가이샤 피리딘 고리 함유 화합물, 및 할로겐화피콜린 유도체 및 테트라졸릴옥심 유도체의 제조 방법
JP2014139184A (ja) * 2010-03-12 2014-07-31 Nippon Soda Co Ltd 臭化ピコリン誘導体の製造方法
CN102791691A (zh) * 2010-03-12 2012-11-21 日本曹达株式会社 含有吡啶环的化合物、及卤代甲基吡啶衍生物以及四唑基肟衍生物的制造方法
CN104072408A (zh) * 2010-03-12 2014-10-01 日本曹达株式会社 含有吡啶环的化合物、及卤代甲基吡啶衍生物以及四唑基肟衍生物的制造方法
US8841458B2 (en) 2010-03-12 2014-09-23 Nippon Soda Co., Ltd. Compound containing pyridine ring and method for producing halogenated picoline derivative and tetrazolyloxime derivative
CN104130184A (zh) * 2010-03-12 2014-11-05 日本曹达株式会社 含有吡啶环的化合物、及卤代甲基吡啶衍生物以及四唑基肟衍生物的制造方法
JP5627038B2 (ja) * 2010-03-12 2014-11-19 日本曹達株式会社 ピリジン環含有化合物
US8962848B2 (en) 2010-03-12 2015-02-24 Nippon Soda Co., Ltd. Compound containing pyridine ring and method for producing halogenated picoline derivative and tetrazolyloxime derivative
WO2011111831A1 (ja) * 2010-03-12 2011-09-15 日本曹達株式会社 ピリジン環含有化合物、及びハロゲン化ピコリン誘導体及びテトラゾリルオキシム誘導体の製造方法
US9000178B2 (en) 2010-03-12 2015-04-07 Nippon Soda Co., Ltd. Compound containing pyridine ring and method for producing halogenated picoline derivative and tetrazolyloxime derivative
US9012653B2 (en) 2010-03-12 2015-04-21 Nippon Soda Co., Ltd. Compound containing pyridine ring and method for producing halogenated picoline derivative and tetrazolyloxime derivative
WO2012171488A1 (en) * 2011-06-17 2012-12-20 Beijing Hanmi Pharmaceutical Co., Ltd. Coumarin derivative, pharmaceutical composition and use thereof
US9133174B2 (en) 2011-09-05 2015-09-15 Chugai Seiyaku Kabushiki Kaisha Method for producing coumarin derivative
WO2013035754A1 (ja) 2011-09-05 2013-03-14 中外製薬株式会社 クマリン誘導体の製造方法
JPWO2013035754A1 (ja) * 2011-09-05 2015-03-23 中外製薬株式会社 クマリン誘導体の製造方法
US9365533B2 (en) 2012-09-21 2016-06-14 Nippon Zoki Pharmaceutical Co., Ltd. Coumarin derivative
WO2014046224A1 (ja) * 2012-09-21 2014-03-27 日本臓器製薬株式会社 クマリン誘導体
JPWO2014046224A1 (ja) * 2012-09-21 2016-08-18 日本臓器製薬株式会社 クマリン誘導体
JP2016516702A (ja) * 2013-03-13 2016-06-09 ザ リージェンツ オブ ザ ユニバーシティー オブ ミシガン Ｍｅｋ／ｐｉ３ｋ二重阻害剤および該阻害剤を使用する治療方法
JP2015193610A (ja) * 2014-03-20 2015-11-05 日本臓器製薬株式会社 クマリン誘導体を含有する医薬
WO2017024167A1 (en) 2015-08-04 2017-02-09 Dow Agrosciences Llc Process for fluorinating compounds
US11400090B2 (en) 2017-11-16 2022-08-02 The Institute Of Cancer Research: Royal Cancer Hospital Coumarin derivative for therapy or prophylaxis of a cell proliferative disorder
WO2019096397A1 (en) 2017-11-16 2019-05-23 The Institute Of Cancer Research: Royal Cancer Hospital Coumarin derivative for therapy or prophylaxis of a cell proliferative disorder
WO2019096449A1 (en) 2017-11-16 2019-05-23 The Institute Of Cancer Research: Royal Cancer Hospital Coumarin derivative for therapy or prophylaxis of a cell proliferative disorder
KR20240093888A (ko) 2017-11-16 2024-06-24 디 인스티튜트 오브 캔서 리서치:로얄 캔서 하스피틀 세포 증식성 질환의 치료 또는 예방을 위한 쿠마린 유도체
KR20200096538A (ko) 2017-11-16 2020-08-12 디 인스티튜트 오브 캔서 리서치:로얄 캔서 하스피틀 세포 증식성 질환의 치료 또는 예방을 위한 쿠마린 유도체
EP3594199A1 (en) 2018-07-09 2020-01-15 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Crystalline 2-fluoro-3-nitrotoluene and process for the preparation thereof
WO2020011626A1 (en) 2018-07-09 2020-01-16 F.I.S. - Fabbrica Italiana Sintetici S.P.A. Crystalline 2-fluoro-3-nitrotoluene and process for the preparation thereof
WO2021048339A1 (en) 2019-09-13 2021-03-18 The Institute Of Cancer Research: Royal Cancer Hospital Vs-6063 in combination with ch5126766 for the treatment of cancer
WO2021047783A1 (en) 2019-09-13 2021-03-18 The Institute Of Cancer Research: Royal Cancer Hospital Vs-6063 in combination with ch5126766 for the treatment of cancer
US11517573B2 (en) 2019-09-13 2022-12-06 The Institute Of Cancer Research: Royal Cancer Hospital Therapeutic compositions, combinations, and methods of use
CN114560774A (zh) * 2020-11-27 2022-05-31 瑞博(杭州)医药科技有限公司 一种2-氟-3-硝基苯甲酸的合成方法
WO2023133472A1 (en) * 2022-01-06 2023-07-13 Immuneering Corporation Mek immune oncology inhibitors and therapeutic uses thereof
US11873296B2 (en) 2022-06-07 2024-01-16 Verastem, Inc. Solid forms of a dual RAF/MEK inhibitor

Also Published As

Publication number Publication date
KR101511396B1 (ko) 2015-04-13
JPWO2009014100A1 (ja) 2010-10-07
EP2172198A1 (en) 2010-04-07
US8569378B2 (en) 2013-10-29
JP5325103B2 (ja) 2013-10-23
KR20100042623A (ko) 2010-04-26
US20110009398A1 (en) 2011-01-13
EP2172198A4 (en) 2012-01-04
EP2172198B1 (en) 2014-04-16

Similar Documents

Publication Publication Date Title
WO2009014100A1 (ja) ｐ２７蛋白質誘導剤
WO2006039164A3 (en) Novel cyclosporin analogues and their pharmaceutical uses
EP1864665A4 (en) IMMUNOSUPPRESSIVE AGENT AND ANTI-TUMOR AGENT COMPRISING A HETEROCYCLIC COMPOUND AS ACTIVE INGREDIENT
WO2005110410A3 (en) Kinase inhibitors as therapeutic agents
WO2006027711A3 (en) Prodrugs and codrugs containing bio- cleavable disulfide linkers
WO2008108380A3 (en) Pyrrole compounds
WO2009020140A1 (ja) アダマンチルウレア誘導体
WO2007048064A3 (en) Amino-pyrimidines as casein kinase ii (ck2) modulators
WO2005105096A3 (en) Fused heterocyclic compounds
EP1704856A4 (en) PROTEIN INHIBITOR OF THE HSP90 FAMILY
WO2008071918A8 (en) Pyrido-pyrazine derivatives useful as herbicidal compounds
WO2005046589A3 (en) Pharmaceutically acceptable salts of quinolinone compounds having improved pharmaceutical properties
WO2007117465A3 (en) Indazole compounds
WO2006113552A8 (en) Cyanoarylamines
AU2009258496A8 (en) Sulfur-containing heterocyclic derivative having beta-secretase-inhibiting activity
WO2005097788A3 (en) Sulfonamides and uses thereof
EA201000050A1 (ru) Замещенные бициклолактамные соединения
WO2003076458A3 (en) Selective dipeptide inhibitors of kallikrein
WO2008102908A1 (ja) ハロアルキルスルホンアニリド誘導体
WO2006067103A3 (en) Process for the preparation of a 2-pyridylethylcarboxamide derivative
NO20052074L (no) Substituerte benzoksazinoner og anvendelser derav.
WO2007099548A3 (en) Novel 11 beta - hydroxyandrosta-4-ene-3-ones
WO2006041631A3 (en) Novel cyclosporin alkynes and their utility as pharmaceutical agents
WO2005085236A3 (en) Caspase inhibitors and uses thereof
WO2006081431A3 (en) Compounds for treating inflammatory and demyelinating diseases

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08791362

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2009524476

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20107000227

Country of ref document: KR

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008791362

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12669944

Country of ref document: US